By Connor Hart
Zscaler narrowed its loss and posted higher revenue in its fiscal 1Q, but its current-quarter outlook failed to impress investors. The cloud-security company guided for adjusted earnings between 68 cents a share and 69 cents a share, as well as revenue between $633 million and $635 million, both of which just met analyst expectations. Shares fall 7.8%, to $192.25, in after-hours trading.
Janux Therapeutics' prostate cancer treatment was selected for expansion trials following what the company called encouraging efficacy and safety results. The treatment, called JANX007, resulted in high prostate-specific antigen response rates and deep prostate-specific antigen declines across all doses in a Phase 1a clinical trial. Shares surge 58%, to $63.60, in post-market trading.
TransMedics lowered its full-year outlook. The Andover, Mass., medical-technology company now expects full-year revenue between $428 million and $432 million, down from its previous outlook of between $425 million and $445 million. Analysts surveyed by FactSet are looking for $431.9 million. Shares fall 9.1%, to $77.40, in after-hours trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 02, 2024 18:36 ET (23:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。